Tom Holvoet
About
Tom Holvoet is a scholar working on Genetics, Surgery and Epidemiology.
According to data from OpenAlex, Tom Holvoet has authored 26 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Surgery and 10 papers in Epidemiology. Recurrent topics in Tom Holvoet's work include Inflammatory Bowel Disease (12 papers), Microscopic Colitis (8 papers) and Gastrointestinal motility and disorders (5 papers). Tom Holvoet is often cited by papers focused on Inflammatory Bowel Disease (12 papers), Microscopic Colitis (8 papers) and Gastrointestinal motility and disorders (5 papers). Tom Holvoet collaborates with scholars based in Belgium, Spain and United Kingdom. Tom Holvoet's co-authors include Pieter Hindryckx, Martine De Vos, Lien Van den Bossche, Sophie Van Welden, Sarah Devriese, Debby Laukens, Lindsey Devisscher, Martine De Vos, Hans Van Vlierberghe and Danny De Looze and has published in prestigious journals such as Gastroenterology, Applied and Environmental Microbiology and Hepatology.
In The Last Decade
Tom Holvoet
22 papers receiving 663 citations
Peers
Tom Holvoet
Laura Harrell United States
Ray Boyapati Australia
P. Cazzola Italy
Guangming Huang China
Seung Wook Hong South Korea
Manuel B. Braga Neto United States
Anna Carrasco Spain
Roni Weisshof United States
Preetika Sinh United States
Sanchuan Lai China
Citations per year, relative to Tom Holvoet Tom Holvoet (= 1×)
peers
Laura Harrell
Countries citing papers authored by Tom Holvoet
Since
Specialization
Citations
This map shows the geographic impact of Tom Holvoet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Holvoet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Holvoet more than expected).
Fields of papers citing papers by Tom Holvoet
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tom Holvoet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Holvoet. The network helps show where Tom Holvoet may publish in the future.
Co-authorship network of co-authors of Tom Holvoet
This figure shows the co-authorship network connecting the top 25 collaborators of Tom Holvoet. A scholar is included among the top collaborators of Tom Holvoet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Holvoet. Tom Holvoet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vieujean, Sophie, Filip Baert, Michaël Somers, et al.. (2025). P0949 Long term real-world effectiveness and safety of upadacitinib in patients with moderate to severe Crohn’s disease: A Belgian multi-centric refractory cohort. Journal of Crohn s and Colitis. 19(Supplement_1). i1773–i1774.
2.
Moens, Annick, Tom Holvoet, Patrick M. Bossuyt, et al.. (2025). P1008 Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab. Journal of Crohn s and Colitis. 19(Supplement_1). i1866–i1867.
3.
Holvoet, Tom, Marie Truyens, Harald Peeters, et al.. (2024). Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. Journal of Clinical Medicine. 13(2). 365–365.
4.
Holvoet, Tom, Bram Verstockt, Mette Julsgaard, et al.. (2024). P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series. Journal of Crohn s and Colitis. 18(Supplement_1). i1186–i1187.
5.
Boeykens, Kurt, et al.. (2023). Nasogastric tube insertion length measurement and tip verification in adults: a narrative review. Critical Care. 27(1). 317–317.
6.
Halkjær, Sofie Ingdam, Bobby Lo, Frederik Cold, et al.. (2023). Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. World Journal of Gastroenterology. 29(20). 3185–3202.
7.
Holvoet, Tom, et al.. (2022). Spontaneous perforated duodenal diverticulum: a case series. Acta Gastro Enterologica Belgica. 85(2). 387–389.
8.
Truyens, Marie, Harald Peeters, Ainara Elorza, et al.. (2022). The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study. Journal of Crohn s and Colitis. 16(11). 1676–1686.
9.
Peeters, Harald, Marie Truyens, Ainara Elorza, et al.. (2021). Safety of vedolizumab and ustekinumab in elderly IBD patients : a real-life multicentric cohort study. Ghent University Academic Bibliography (Ghent University).
10.
Holvoet, Tom, Triana Lobatón, & Pieter Hindryckx. (2021). Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clinical and Experimental Gastroenterology. Volume 14. 71–81.
11.
Holvoet, Tom, Marie Joossens, Jorge F. Vázquez‐Castellanos, et al.. (2020). Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology. 160(1). 145–157.e8.
12.
Holvoet, Tom, Sarah Devriese, Karolien Castermans, et al.. (2017). Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor. Gastroenterology. 153(4). 1054–1067.
13.
Bossche, Lien Van den, Sarah Devriese, Sophie Van Welden, et al.. (2017). Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory conditions and dampens Crohn's disease-like ileitis. Laboratory Investigation. 97(5). 519–529.
14.
Devriese, Sarah, Lien Van den Bossche, Sophie Van Welden, et al.. (2017). T84 monolayers are superior to Caco-2 as a model system of colonocytes. Histochemistry and Cell Biology. 148(1). 85–93.
15.
Vos, Martine De, Séverine Vermeire, Édouard Louis, et al.. (2017). Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterology Journal. 6(3). 439–445.
16.
Bossche, Lien Van den, Pieter Hindryckx, Lindsey Devisscher, et al.. (2017). Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice. Applied and Environmental Microbiology. 83(7).
17.
Bossche, Lien Van den, Pieter Hindryckx, Lindsey Devisscher, et al.. (2017). P777 Ursodeoxycholic acid and its taurine/glycine conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Journal of Crohn s and Colitis. 11(suppl_1). S478–S478.
18.
Hindryckx, Pieter, Barrett G. Levesque, Tom Holvoet, et al.. (2016). Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 67(1). 61–69.
19.
Holvoet, Tom, Sarah Raevens, Yves‐Paul Vandewynckel, et al.. (2015). Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. Digestive and Liver Disease. 47(10). 877–883.
20.
Holvoet, Tom, Jan P. van Meerbeeck, Christophe Van de Wiele, Bihiyga Salhi, & Eric Derom. (2011). Quantitative Perfusion Scintigraphy or Anatomic Segment Method in lung cancer resection. Lung Cancer. 74(2). 212–218.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Laura Harrell Breakdown of academic impact, for papers by Ray Boyapati Breakdown of academic impact, for papers by P. Cazzola Breakdown of academic impact, for papers by Guangming Huang Breakdown of academic impact, for papers by Seung Wook Hong Breakdown of academic impact, for papers by Manuel B. Braga Neto Breakdown of academic impact, for papers by Anna Carrasco Breakdown of academic impact, for papers by Roni Weisshof Breakdown of academic impact, for papers by Preetika Sinh Breakdown of academic impact, for papers by Sanchuan Lai